Related references
Note: Only part of the references are listed.Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab (September, 10.1007/s12072-022-10406-8, 2022)
Takeshi Hatanaka et al.
HEPATOLOGY INTERNATIONAL (2023)
Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Toshifumi Tada et al.
CANCER MEDICINE (2023)
Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
Tetsu Tomonari et al.
CANCER MEDICINE (2023)
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice
Miyuki Nakagawa et al.
CANCER (2023)
Two cases of hepatocellular carcinoma successfully treated by carbon ion radiotherapy after atezolizumab plus bevacizumab treatment
Satoshi Takakusagi et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2023)
A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy
Atsushi Naganuma et al.
CLINICAL JOURNAL OF GASTROENTEROLOGY (2022)
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis
Tetsu Tomonari et al.
HEPATOLOGY RESEARCH (2021)
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
A. Vogel et al.
ANNALS OF ONCOLOGY (2021)
Two hepatectomy cases for initially unresectable hepatocellular carcinoma after achieving a radiological complete response to sequential therapy with lenvatinib and transcatheter arterial chemoembolization
Kei Endo et al.
HEPATOLOGY RESEARCH (2021)
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib
Toshifumi Tada et al.
SCIENTIFIC REPORTS (2021)
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
Masatoshi Kudo et al.
LIVER CANCER (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array
Tetsu Tomonari et al.
Oncotarget (2020)
Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib Three case reports
Tetsu Tomonari et al.
MEDICINE (2020)
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Kazuomi Ueshima et al.
CANCERS (2019)
Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma
Hideaki Takeyama et al.
SURGERY TODAY (2018)
The role of molecular enrichment on future therapies in hepatocellular carcinoma
Jean-Charles Nault et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Kenji Ikeda et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda et al.
CLINICAL CANCER RESEARCH (2016)
RECIST 1.1-Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials
Hongliang Zhang et al.
ONCOTARGET (2016)
Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients
Antonio Facciorusso et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation
Antonio Facciorusso et al.
DIGESTIVE AND LIVER DISEASE (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Share Paper
